Get started
Author

Konrad Tałasiewicz

Observed names: K. Talasiewicz, K. Tałasiewicz, Konrad Talasiewicz
ORCID: 0000-0001-6575-8005
Observed ORCID: 0000-0001-6575-8005
OpenAlex ID: A5084961245
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
2023 · Kim N. Chi, Dana Rathkopf, et al. · Journal of Clinical Oncology · 357
Progressive transformation of germinal centers: an illustration of two clinical cases
2018 · Konrad Tałasiewicz, Aleksandra Czachowska, et al. · Annals of Hematology · 8
PDF
Anemia in cancer patients: addressing a neglected issue – diagnostics and therapeutic algorithm
2023 · Konrad Tałasiewicz, Aleksandra Kapała · Nowotwory Journal of Oncology · 7
PDF
Evaluation of knowledge about acne vulgaris among a selected population of adolescents of Tricity schools
2012 · Konrad Tałasiewicz, Agnieszka Ołdakowska, et al. · Advances in Dermatology and Allergology · 5
PDF
Systemic complications in the hormonal treatment of prostate and breast cancer
2017 · Beata Jagielska, Grażyna Poniatowska, et al. · Nowotwory Journal of Oncology · 1
PDF
Are molecular target therapies limited by cardiotoxicity — causes and symptoms of cardiovascular damage
2017 · Beata Jagielska, Konrad Tałasiewicz, et al. · Nowotwory Journal of Oncology · 1
PDF
De-escalated total neoadjuvant therapy for the non-operative management of rectal cancer: Results of the NOM-3/TNT prospective cohort study
2026 · Bartłomiej Skrzypiec, Karol Paciorek, et al. · Clinical and Translational Radiation Oncology
Cancer without a map: Navigating cancer of unknown primary through molecular profiling
2026 · Konrad Tałasiewicz, Michał Mikula, et al. · Critical Reviews in Oncology/Hematology
Ten-Year Experience in the Treatment of Cancers of Unknown Primary from Poland: From Overall Survival to Factors Influencing Response in the Prepersonalization Era
2026 · Konrad Tałasiewicz, Aleksandra Czachowska, et al. · Cancers
PDF
1070P Neutrophil-to-lymphocyte ratio predicts survival in patients with cancer of unknown primary
2020 · K. Tałasiewicz, A. Czachowska, et al. · Annals of Oncology
Comparison of venous thromboembolism risk assessment models in patients receiving chemotherapy
2018 · K. Talasiewicz, P. Ozdowska, et al. · Annals of Oncology
PDF
Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS)
2018 · Beata Jagielska, Andrzej Czubek, et al. · Journal of Green Engineering
Survival outcomes for polish women younger than age 40 years receiving trastuzumab for HER2-positive early breast cancer: A National population-based observational study.
2018 · Beata Jagielska, Agnieszka Irena Jagiello-Gruszfeld, et al. · Journal of Clinical Oncology
Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS)
2018 · Beata Jagielska, Andrzej Czubek, et al. · Molecular and Cellular Therapies
Multiple brown tumors in the course of primary hyperparathyroidism mimicking bone metastases – case report
2018 · Konrad Tałasiewicz, Aleksandra Czachowska, et al. · Oncology in Clinical Practice
Mnogie guzy brunatne w przebiegu pierwotnej nadczynności przytarczyc imitujące zmiany przerzutowe w kościach — opis przypadku
2018 · Konrad Tałasiewicz, Aleksandra Czachowska, et al. · Via Medica Journals
PDF
Powikłania ogólnoustrojowe leczenia hormonalnego chorych na raka gruczołu krokowego i raka piersi
2017 · Beata Jagielska, Grażyna Poniatowska, et al. · Via Medica Journals
PDF
Works count: 18
Citation count: 379
H-index: 4
I10-index: 1
Year
Topic
Type